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Introduction
Uncontrolled bleeding in trauma or major surgery (e.g. cardiac, 
liver, orthopedic) leads to a loss of coagulation factors and bears an 
additional risk for further dilution of coagulation factors by volume 
replacement. Dilutional coagulopathy impairs coagulation and, if 
not recognized and promptly and adequately treated by rapid he-
mostatic interventions, will lead to exsanguination. In 2010 the 
World Health Organization (WHO) recommended to start using 
transfusion alternatives and to develop individualized patient blood 
management programs to reduce transfusion requirements. The 
patient blood management program consists of three main consid-
erations for management: i) detection and treatment of preopera-
tive anemia, ii) reduction in perioperative RBC loss, and iii) opti-
mizing the patient-specific physiological reserve of anemia (includ-
ing restrictive hemoglobin transfusion triggers) [1–5].
The purpose of this review is to review the optimal bleeding 
management by using point of care (POC) devices and transfusion 
algorithms. This aspect is of major importance as adverse outcome 
related to blood products (red blood cells (RBCs), fresh frozen 
plasma (FFP), and platelets) has been proven. The costs can be sig-
nificantly reduced by lowering blood product administration 
which may also have the potential to decrease length of hospital 
stay and to prevent serious adverse events such as infections. Al-
though standard laboratory coagulation tests are widely used to 
determine coagulopathy in the operating room and for trauma pa-
tients in the emergency department, their diagnostic value in the 
acutely bleeding patient is limited based on turnaround time. 
Moreover, they have limited predictive value for bleeding and were 
not developed for the use in actively bleeding patients [6]. 
The use of POC devices includes whole blood assays such as ro-
tational thromboelastometry or thromboelastography, platelet 
mapping or platelet aggregometry, and international normalized 
ratio (INR) / prothrombin time (PT) that will be briefly highlighted 
in this review [7–9].
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Summary
In the last years it has become evident that the use of 
blood products should be reduced whenever possible. 
There is increasing evidence regarding serious adverse 
events, including higher mortality and morbidity, related 
to transfusions. The use of point of care (POC) devices 
integrated in algorithms is one of the important mecha-
nisms to limit blood product exposure. Any type of algo-
rithm, especially the POC-based ones, allows goal-di-
rected transfusions of blood products and even better 
targeted factor concentrate substitutions. Different types 
of algorithms in different surgical settings (cardiac sur-
gery, trauma, liver surgery etc.) have been established 
with growing interest in their use as they offer objective 
therapy for management and reduction of blood product 
use. The use of POC devices with evidence-based algo-
rithms is important in the bleeding patient independent 
of its origin (traumatic vs. surgical). The use of factor 
concentrates compared to the classical blood products 
can be cost-saving, beneficial for the patient, and in 
agreement with the WHO-requested standard of care. 
The empiric and uncontrolled use of blood products 
such as fresh frozen plasma, red blood cells, and plate-
lets without POC monitoring should no longer be fol-
lowed with regard to actual evidence in literature. Fur-
thermore, the use of factor concentrates may provide 
better outcomes and potential for cost saving.
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Point of Care Testing
PT POC Testing – e.g. CoaguChek®
Besides the CoaguChek® (Roche Diagnostics, Mannheim, Ger-
many), there are various other INR POC devices on the market but 
because of its use in our institution we stuck to this one. CoaguChek 
measures the INR and Quick value (In many countries, blood coag-
ulability is expressed in a unit named Quick value. The measured PT 
is expressed in relation to the coagulation time of a healthy person. 
The value obtained is the ‘percentage of the standard value’. In a 
person not receiving oral anticoagulation the ‘normal’ Quick value is 
between 70 and 100%, but might be different depending on the rea-
gent used according to the calibration against the WHO ‘standard’) 
in whole blood within 1 min after the addition of 8 μl of blood to the 
device. These two values are calculated back by the device from a 
programmed calibrator result. Normally, these results would take 30 
to 60 min to be available from the standard laboratory and are ob-
tained by using citrated cell-free plasma. The PT represents the co-
agulation time in a system that was ‘extrinsically’ activated via fac-
tors VII, V and X and the activation of prothrombin to thrombin, 
which converts fibrinogen to fibrin. This device is ideal to monitor 
patients taking vitamin K antagonists (e.g. warfarin) in the emer-
gency department, in cardiovascular surgery, in acutely bleeding pa-
tients, or in patients with traumatic brain injury; the test can be used 
for rapid diagnosis and therapy with factor concentrates to rapidly 
reverse the anticoagulation. The device is also validated to guide 
outpatient oral anticoagulation (vitamin K antagonists). In the peri-
operative setting and the emergency department, however, evidence 
supporting its use is limited to case series. In 17 patients needing 
emergency surgery (burr hole, craniotomy, or laminectomy), the an-
ticoagulation was assessed and reversed before the intervention 
using this assay. The measurements on the CoaguChek correlated 
well with the laboratory values, and the mean time gained using the 
POC assay was 47 min [10]. In other settings like war casualties the 
time gained using this assay was approximately 26 min compared to 
the laboratory [11]. In ischemic strokes, time to lysis and detection 
of oral anticoagulants was reduced [12], and in patients after cardio-
pulmonary bypass PT was determined much earlier than by the lab-
oratory by using this type of POC device [13]. 
Clot Formation in Whole Blood Thromboelastography and  
Rotational Thromboelastometry
The preliminary and most important statement regarding the 
use of these devices is that, regardless of which results are obtained 
– even if they are pathological –, a non-bleeding patient needs no 
therapeutic intervention. All standard coagulation tests in the labo-
ratory are measured in plasma and assess usually extrinsic and an 
intrinsic pathways using PT and partial thromboplastin time, re-
spectively. Only the clotting time is measured, giving no informa-
tion about the following development or stability of the blood clot.
In 1948 Hartert [14] first presented a method to measure the 
formation of a clot from whole blood. Almost 50 years passed until 
thromboelastography (TEG® by Hemoscope Corporation, Niles, 
IL, USA) and rotational thromboelastometry (ROTEM®; initially 
by Pentapharm, now TEM International GmbH, Munich, Ger-
many) were developed and made registered trademarks in 1996 
and 2000, respectively. Today, these two systems are the most com-
monly used POC devices for whole blood coagulation diagnostic 
testing in trauma, liver surgery, cardiac surgery, post-partum hem-
orrhage, and many other settings. They provide valuable informa-
tion about clot initiation, formation, and lysis corresponding to 
platelet number and function, fibrinogen quantity and function as 
well as pro- and anticoagulation enzymes. Measurements are usu-
ally made using citrated whole blood. Reagents and whole blood 
are pipetted and incubated in heated (37 °C) small cups. A pin is 
introduced into the sample measuring the changes of the viscoelas-
tic properties of the forming blood clot. In TEG, the cup oscillates 
with an angle of 4.45°, and the consecutive movement of the pin is 
translated into an electric signal by a torsion wire. In ROTEM, the 
cup is stationary and the pin moves 4.75°; the impedance of pin 
rotation is measured by an optical detector [15]. Information is 
gained by the initiation of clot formation, clot formation itself, 
maximum clot firmness, and clot lysis. Terminology in TEG and 
ROTEM is different and summarized in table 1.
The ROTEM device can measure 4 channels in parallel. Five 
commonly used different tests can be started, and the clot forma-
tion can be visualized. With EXTEM, coagulation is started by the 
addition of tissue factor, representing the classical extrinsic path-
way activation. With INTEM, coagulation is initiated by contact 
Table 1. Differences in terms between ROTEM and TEG from Theusinger et al., 2013 [65]
Parameter ROTEM TEG
Clot time period to 2 mm amplitude clotting time (CT) retraction time (R)
Clot kinetics period from 2 to 20 mm amplitude clot formation time (CFT) kinetics (K)
α-angle slope of tangent at 2 mm amplitude (α) slope between R and K (α)
Maximum clot strength maximum clot firmness (MCF) maximum amplitude (MA)
Clot elasticity maximum clot elasticity (MCE) G
Lysis at certain points of time amplitude reduction after 30 or 60 min  
after MCF (CL30, CL60)
amplitude reduction after 30 or 60 min  
after MA (Ly30, Ly60)
Clot lysis maximum lysis (ML) estimated percent lysis (EPL)
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activator leading to intrinsic pathway activation. The inhibition of 
the platelets by cytochalasin D in the FIBTEM test shows the fi-
brinogen clotting which corresponds to fibrinogen plasma levels 
and can be visualized [16, 17]. Furthermore the amount of factor 
XIII plays a role regarding the maximal amplitude of this test [18]. 
No effect of platelets should be present anymore as they were com-
pletely inhibited by cytochalasin D.
The addition of aprotinin, which is called APTEM test, inhibits 
fibrinolysis, and addition of heparinase before contact activation 
visualizes a heparin effect in the HEPTEM test.
In most active bleeding patient the first substrate to drop below 
critical levels will be fibrinogen. ROTEM is capable to determine 
indirectly fibrinogen concentration (as 7 mm correspond to 1.5 
g/l, a curve regarding this correlation exists in the literature) 
within 10 min, which normally takes 30–60 min in the laboratory, 
and the efficacy of treatment can be readily determined [7, 19–22]. 
Hyperfibrinolysis can be readily detected by TEG and ROTEM. 
Reduction of clot strength or complete lysis after formation is the 
in vitro equivalent of pathological activation of fibrinolysis. 
Trauma patients with hyperfibrinolysis documented by ROTEM 
have a significantly higher mortality compared to those without 
[23]. Hyperfibrinolysis > 3% is associated with massive transfu-
sion [24]. Fibrinogen substitution as a substrate and prothrombin 
complex concentrate as an enzyme, guided by rotational thromb-
elastometry, can be safely used to enhance thrombin generation 
in patients with severe multiple trauma [25–27]. Moreover the 
FIBTEM value can be used to predict massive transfusion in 
trauma [28]. ROTEM-guided coagulation management was asso-
ciated with reduced transfusion rates of allogeneic blood products 
[21]. In pediatric cardiac surgery, thrombelastometry-guided co-
agulation management reduced bleeding and the use of allogeneic 
RBC transfusion and length of stay on the intensive care unit [29]. 
However, these tests are not readily suited for monitoring the oral 
anticoagulant agents. Also, vitamin K antagonists are not readily 
measured unless severely over-anticoagulated. Novel or directly 
acting oral anticoagulants alter viscoelastic tests. Their exact effect 
is difficult to quantify, although work is underway to develop spe-
cific tests [30].
Qualification and Quantification of Platelet Function or 
Inhibition
Different POC devices dealing with platelet function exist. The 
PFA-100® (Siemens Healthcare, Malvern, PA, USA) measures 
platelet adhesion, mimicking arterial high shear stress. Addition of 
whole blood measures a ‘closure time’ in collagen/epinephrine and 
collagen/ADP test cartridges. Information about inborn platelet 
function defects and von Willebrand disease can be obtained from 
this test [31]. However, its use in a bleeding and coagulopathic pa-
tient is not well characterized as many of these tests may not work 
with dilutional coagulopathy.
Multiplate® and TEG platelet mappingTM are POC devices to 
detect and quantify the effect of antiplatelet medication. Inhibition 
of the arachidonic acid pathway, the GPIIb/IIa pathway, and the 
ADP (P2Y12) receptor pathway can be measured.
Multiplate® (Roche Diagnostics International Ltd, Rotkreuz, 
Switzerland) visualizes electrode coating by aggregated platelets 
leading to aggregation units (over time). Low volumes of whole 
blood in five channels (dual sensors) measure platelet inhibition by 
stimulation with arachidonic acid (ASPItest), adenosine diphos-
phate (ADPtest), collagen (COLtest), and thrombin receptor-acti-
vating peptide (TRAPtest).
The number of patients treated with antiplatelet drugs due to 
cardiovascular or cerebrovascular disease is continuously in-
creasing [32]. New ADP receptor antagonists with specific phar-
macokinetic and pharmacodynamic profiles like Ticagrelor® 
make a quantification of the clinical antiplatelet effect critical. 
Even for high-risk patients with drug-eluting stents needing 
emergency surgery, POC testing may be desired to guide a bridg-
ing protocol when one or two of the antiplatelet drugs are to be 
discontinued. Moreover, patients not responding to clopidogrel 
treatment can be identified [33]. Some institutions treat these 
 patients without using these devices – the standard of care has to 
be determined yet. 
After on-pump aorto-coronary bypass (CABG) surgery, TEG 
platelet mapping was able to predict excessive postoperative chest 
tube bleeding (CTB) and the need for platelet transfusion [34], but 
failed to correlate with 24-hour CTB [35]. Other platelet function 
testing failed to predict postoperative bleeding in patients with 
P2Y12 inhibitors [36, 37]. PFA-100 had a high negative predictive 
value of 98% to identify patients not needing platelet transfusions 
post cardiac bypass [38]. VerifyNow® (Accumetrics, San Diego, 
CA, USA) platelet function assay predicted the need for RBC trans-
fusion, but not the need for platelet transfusion post CABG [39]. 
Platelet dysfunction measured by POC (collagen-activated platelet 
count) during rewarming was associated with high (>1,770 ml) 
blood loss in a cohort of 100 patients [40].
In neurosurgery, antiplatelet drugs were a risk factor for re-
bleeding after neurosurgical procedures [41]. Patients with im-
paired platelet function due to aspirin intake had higher mortality 
in the case of spontaneous intracranial hemorrhage [42]. Inability 
to normalize the VerifyNow aspirin assay value was associated with 
a trend towards higher mortality [43]. Of note, the use of platelet 
transfusions to normalize platelet function in patients with intra-
cranial hemorrhage did not show a positive effect on patient out-
come in retrospective analyses [44, 45].
In severe brain trauma, platelet dysfunction was present due to 
a significantly increased inhibition of platelet ADP and arachi-
donic acid receptors [46]. In 46 trauma patients reported to be 
taking clopidogrel, the platelet inhibitory effect was measured with 
VerifyNow (P2Y12). Patients with low (<30%) platelet inhibition 
by clopidogrel did not die due to bleeding and had low rates of 
 increased intracranial hemorrhage [47]. Using the multiple elec-
trode aggregometry in 163 trauma patients, a retrospective analy-
sis identified significant difference in the ADPtest between sur-
vivors and non-survivors [48]. The latest device, named TEM 
Platelet®, was developed by TEM International GmbH (Munich, 
Germany); this two-channel device measures platelet function by 
aggregometry and can be added to the ROTEM, allowing to meas-
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ure in total 6 channels with complete coagulation assessment and 
platelet function. POC monitoring of blood coagulation at the 
bedside is not only desirable but also is becoming increasingly 
 recommended [7].
Factor Concentrates 
The use of FFP leads to adverse effects, including increased 
mortality, multiple organ failure, risk of infection, lung injury, 
and immunomodulation [49, 50]. The effectiveness of FFP com-
pared to fibrinogen concentrate regarding clinical endpoints as 
blood loss, transfusion requirements, hospital length of stay, sur-
vival and plasma fibrinogen concentration favors fibrinogen con-
centrates [49]. For this reason fibrinogen and potentially other 
factor concentrates should be considered in patients with sub-
stantial bleeding [7].
This consideration is based on target levels of fibrinogen for 
trauma patients that have been defined at 1.5–2.0 g/l in the Euro-
pean Trauma Treatment Guidelines [7]. Administration of fibrino-
gen concentrates is advantageous compared to FFP transfusion as 
fibrinogen concentration in FFP is variable (about 2 g/l on aver-
age), and large volumes of FFP would be necessary to effectively 
increase the fibrinogen concentration to achieve target fibrinogen 
concentrations of 1.5–2.0 g/l [51]. When replacing most FFP trans-
fusions with fibrinogen concentrate, monitoring factor XIII levels 
is also advisable after the replacement of approximately 50% of the 
blood volume as this will be the moment when factor XIII reaches 
a critical level. A 60% factor XIII activity level is advised to be 
maintained by the administration of factor XIII concentrate [19, 
52–54]. 
Besides single-factor concentrates, prothrombin complex con-
centrates (PCCs) are also part of factor-based algorithms [19, 21, 
22, 32, 56, 55]. Individual PCCs differ regarding their factors con-
tained, their relative composition, and their thrombotic potential. 
Although PCCs are approved for vitamin K antagonist reversal 
[57], their use is also suggested by the update of the European 
Trauma Guidelines in 2013 if the initiation of clot formation is 
prolonged in rotational thromboelastometry [7]. PCC should be 
used only within a strict algorithm, the dose should be small, and 
repeat doses should be given with caution to minimize thrombotic 
risks [56]. Of note, studies indicate that significant reductions in 
RBCs, FFP and platelets transfusions can be facilitated by using a 
coagulation factor concentrate-based coagulopathy management 
in trauma patients [58]. Based upon data from four European 
countries (UK, Germany, Italy, and Switzerland), blood substitu-
tion levels and blood products were calculated and found to ac-
count for approximately 27% of all costs associated with trauma 
care on the intensive care unit [59]. Additional findings include a 
reduction in septic complications and organ failure which trans-
lated into trends towards reduced ventilator time and shorter over-
all inhospital length of stays. These important findings may also 
contribute to cost reduction in acute trauma care without increas-
ing the risk for the individual patient. 
Algorithms Used
The first types of algorithm published used TEG/ROTEM to 
guide the administration of blood products such as platelets and 
FFP. They were all able to reduce blood product use and costs. 
Most studies were first performed in cardiac surgery in 1994. In 
table 2 a brief overview of the first publications is given regarding 
cost-savings. 
However, depending on the country, different factor concen-
trates may not be available. The following examples show sophis-
ticated  algorithms which give clear instructions regarding the 
treatment of a bleeding patient depending on the results given by 
POC devices. Görlinger et al. [32] published in 2011 their 5-year 
experience in cardiac surgery in Essen, Germany. The used an 
 algorithm in which ROTEM and Multiplate was integrated and 
which gave clearly structured therapeutical instructions. Thus 
they were able to significantly reduce the use of any allogeneic 
blood transfusion (52.5 vs. 42.2%; p < 0.0001), of packed RBCs 
(49.7 vs. 40.4%; p < 0.0001), and of FFP (19.4 vs. 1.1%; p < 0.0001). 
The amount of platelets transfused (10.1 vs. 13.0%; p = 0.0041) as 
well as the administration of fibrinogen concentrate (3.73 vs. 
10.01%; p < 0.0001) and PCC (4.42 vs. 8.9%; p < 0.0001) increased 
significantly. During the course of the study, a switch from apro-
tinin to tranexamic acid occurred as well as an increase in the use 
of dual antiplatelet therapy (2.7 vs. 13.7%; p < 0.0001); as a conse-
quence the incidence of massive (˰10 U packed RBCs) transfu-
Table 2. Cost / blood product savings by the first published algorithms using POC devices
Publication Type Year Field Patients Mortality Savings of cost
O’Keeffe et al. [66] retrospective 2008 trauma 132 52.3% 22%
Despotis et al.[67] prospective 1994 cardiac 66 n.n. reduction
Spiess et al. [68] retrospective 1995 cardiac 1,079 n.n. USD 50,000.00 in 6 months
Shore-Lesserson et al. [69] prospective 1999 cardiac 92 n.n. blood products –20%
Nuttall et al. [70] prospective 2001 cardiac 58 n.n. FFP and platelets –60%
Capraro et al. [71] prospective 2001 cardiac 58 3% blood products –20%
Royston et al. [72] prospective 2001 cardiac 120 n.n. FPP and platelets –70%
Avidan et al. [73] prospective 2004 cardiac 220 n.n. RBCs, platelets –60%; FFP –90%
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sion (2.5 vs. 1.26%; p = 0.0057) and unplanned re-exploration 
(4.19 vs. 2.24%; p = 0.0007) decreased. Thrombotic and throm-
boembolic events also decreased significantly (3.19 vs. 1.77%; 
p = 0.0115), but inhospital mortality remained identical. 
In another study by Schöchl et al. [21], a ROTEM-guided algo-
rithm was used in trauma patients to compare patients receiving 
FFP versus those receiving fibrinogen concentrates and PPC 
 instead. As hemostatic therapy in the emergency department and 
during surgery the FFP group (injury severity score 35.5 ± 10.5) 
received a median of 6 (range 2–51) units of FFP, while the fibrino-
gen-PCC group (injury severity score 35.2 ± 12.5) received a me-
dian of 6 (range 0–15) g of fibrinogen concentrate and 1,200 (range 
0–6,600) U of PCC. RBC transfusion was avoided in 29% of pa-
tients in the fibrinogen-PCC group, compared with only 3% in the 
FFP group (p < 0.001). Transfusion of platelet concentrate was 
avoided in 91% of patients in the fibrinogen-PCC group, compared 
with 56% in the FFP group (p < 0.001). Mortality was comparable 
in both groups – 7.5% in the fibrinogen-PCC group and 10.0% in 
the FFP group (p = 0.69). This study also showed a clear benefit for 
using an algorithm guided by POC devices.
The third example to be mentioned is the algorithm published 
by Theusinger et al. [60, 61]. This algorithm also takes into consid-
eration different laboratory and POC results, such as ROTEM, 
CoaguCheck and Multiplate, and gives clear treatment orders. De-
pending on the type of surgery – neurosurgery and cardiac surgery 
– versus trauma and others, the threshold values have been adapted 
to take into consideration different bleeding risks. A FIBTEM with 
a maximum clot firmness (MCF) of <7 mm, corresponding to ap-
proximatively 1.5 g/dl of fibrinogen, only needs substitution of 
 fibrinogen if the patient is bleeding; in a non-bleeding patient no 
therapeutic intervention is needed. Platelets need to be above 
100,000/μl in the bleeding patient during neurosurgery and cardiac 
surgery compared to 50,000/μl in all others. This algorithm aims to 
correct pathological values only in case of bleeding and to reach 
normal values at the lower range to avoid thromboembolic compli-
cations. This algorithm also include desmopressin which enhances 
platelet adherence and is the first choice in the treatment of bleed-
ing patients with quantitative deficiency (type 1) and some of the 
qualitative defects (type 2) of von Willebrand factor (vWF) [62, 
63]. Patients treated with aspirin and ADP receptor inhibitors such 
as clopidogrel could also benefit from POC testing to assess the in-
dividual efficacy of desmopressin treatment [64]. In case of in-
sufficient treatment with desmopressin, transfusing platelets is the 
ultimate option. 
Conclusion
The use of POC devices with evidence-based algorithms seems 
mandatory in the bleeding patient independent of bleeding origin 
(traumatic vs. surgical) The use of factor concentrates, compared 
to the classical blood products, is cost-saving and beneficial for the 
patient and also in agreement with the WHO-requested standard 
of care. The uncontrolled use of blood products such as FFP, RBCs 
and platelets without POC control seems to be inadequate with 
 regard to the actual evidence in literature. Furthermore, the use of 
factor concentrates seems to be in favor for better outcome and 
cost saving. 
Disclosure Statement
Oliver M. Theusinger has received honoraria or travel support for consult-
ing or lecturing from the following companies: CSL Behring Schweiz, Zurich, 
Switzerland; Vifor SA, Villars-sur-Glâne, Switzerland; Roche Pharma (Schweiz) 
AG, Reinach, Switzerland; Pentapharm AG, Munich, Germany; TEM Inter-
national, Munich, Germany.
Philipp Stein has no conflict of interest. 
Within the past 3 years Jerrold H. Levy has served or serves on research 
steering committees, data safety monitoring boards, or advisory boards for CSL 
Behring, Boehringer-Ingelheim, Grifols, J&J, Marathon, Merck, Medicines 
Company, Octapharma, Portola, and Roche.
References
 1 Carson JL, Carless PA, Hebert PC: Transfusion thresh-
olds and other strategies for guiding allogeneic red 
blood cell transfusion. Cochrane Database Syst Rev 
2012; 4:CD002042.
 2 Goodnough LT, Shander A: Patient blood manage-
ment. Anesthesiology 2012; 116: 1367–1376.
 3 Shander A, Hofmann A, Isbister J, Van Aken H: Pa-
tient blood management – the new frontier. Best Pract 
Res Clin Anaesthesiol 2013; 27: 5–10.
 4 Spahn DR, Goodnough LT: Alternatives to blood 
transfusion. Lancet 2013; 381: 1855–1865.
 5 Williamson LM, Devine DV: Challenges in the manage-
ment of the blood supply. Lancet 2013; 381: 1866–1875.
 6 Park MS, Martini WZ, Dubick MA, Salinas J, Butenas 
S, Kheirabadi BS, Pusateri AE, Vos JA, Guymon CH, 
Wolf SE, Mann KG, Holcomb JB: Thromboelastogra-
phy as a better indicator of hypercoagulable state after 
injury than prothrombin time or activated partial 
thromboplastin time. J Trauma 2009; 67: 266–276.
 7 Spahn DR, Bouillon B, Cerny V, Coats TJ, Duranteau J, 
Fernandez-Mondejar E, Filipescu D, Hunt BJ, Komad-
ina R, Nardi G, Neugebauer E, Ozier Y, Riddez L, 
Schultz A, Vincent JL, Rossaint R: Management of 
bleeding and coagulopathy following major trauma: an 
updated European guideline. Crit Care 2013; 17:R76.
 8 Davenport R, Manson J, De’Ath H, Platton S, Coates 
A, Allard S, Hart D, Pearse R, Pasi KJ, MacCallum P, 
Stanworth S, Brohi K: Functional definition and char-
acterization of acute traumatic coagulopathy. Crit Care 
Med 2011; 39: 2652–2658.
 9 Johansson PI, Stissing T, Bochsen L, Ostrowski SR: 
Thrombelastography and tromboelastometry in as-
sessing coagulopathy in trauma. Scand J Trauma Re-
susc Emerg Mede 2009; 17: 45.
10 Beynon C, Jakobs M, Rizos T, Unterberg AW, Sako-
witz OW: Rapid bedside coagulometry prior to urgent 
neurosurgical procedures in anticoagulated patients. 
Br J Neurosurg 2014; 28: 29–33.
11 Cotte J, D’Aanda E, Chauvin V, Kaiser E, Meaudre E: 
Point-of-care coagulation testing for trauma patients 
in a military setting: a prospective study. J Spec Oper 
Med 2013; 13: 59–62.
12 Nusa D, Harvey I, Almansouri AY, Wright S, Neeman 
T, Ahmad O, Hughes AR, Lueck CJ: Assessment of 
point-of-care measurement of international normal-
ised ratio using the CoaguChek XS plus system in the 
setting of acute ischaemic stroke. Intern Med J 2013; 
43: 1205–1209.
13 Chavez JJ, Weatherall JS, Strevels SM, Liu F, Snider 
CC, Carroll RC: Evaluation of a point-of-care coagula-
tion analyzer on patients undergoing cardiopulmonary 
bypass surgery. J Clin Anesth 2004; 16: 7–10.
14 Hartert H: Blutgerinnungsstudien mit der Thrombe-
lastographie, einem neuen Untersuchungsverfahren. 
Klin Wochenschr 1948; 26: 577–583.
15 Luddington RJ: Thrombelastography/thromboelastom-
etry. Clin Lab Haematol 2005; 27: 81–90.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
5/
27
/2
01
6 
11
:5
5:
08
 A
M
Theusinger/Stein/LevyTransfus Med Hemother 2015;42:115–121120
16 Theusinger OM, Nurnberg J, Asmis LM, Seifert B, 
Spahn DR: Rotation thromboelastometry (ROTEM) 
stability and reproducibility over time. Eur J Cardio-
thorac Surg 2010; 37: 677–683.
17 Hiippala ST: Dextran and hydroxyethyl starch inter-
fere with fibrinogen assays. Blood Coagul Fibrinolysis 
1995; 6: 743–746.
18 Theusinger OM, Baulig W, Asmis LM, Seifert B, Spahn 
DR: In vitro factor XIII supplementation increases clot 
firmness in rotation thromboelastometry (ROTEM). 
Thromb Haemost 2010; 104: 385–391.
19 Theusinger OM, Madjdpour C, Spahn DR: Resuscita-
tion and transfusion management in trauma patients: 
emerging concepts. Curr Opin Crit Care 2012; 18: 661–
670.
20 Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau 
J, Fernandez-Mondejar E, Hunt BJ, Komadina R, 
Nardi G, Neugebauer E, Ozier Y, Riddez L, Schultz A, 
Stahel PF, Vincent JL, Spahn DR; Task Force for Ad-
vanced Bleeding Care in Trauma: Management of 
bleeding following major trauma: an updated Euro-
pean guideline. Crit Care 2010; 14:R52.
21 Schochl H, Nienaber U, Maegele M, Hochleitner G, 
Primavesi F, Steitz B, Arndt C, Hanke A, Voelckel W, 
Solomon C: Transfusion in trauma: thromboelastome-
try-guided coagulation factor concentrate-based ther-
apy versus standard fresh frozen plasma-based ther-
apy. Crit Care 2011; 15:R83.
22 Theusinger OM, Felix C, Spahn DR: Strategies to re-
duce the use of blood products: a European perspec-
tive. Curr Opin Anaesthesiol 2012; 25: 59–65.
23 Theusinger OM, Wanner GA, Emmert MY, Billeter A, 
Eismon J, Seifert B, Simmen HP, Spahn DR, Baulig W: 
Hyperfibrinolysis diagnosed by rotational thromboe-
lastometry (ROTEM) is associated with higher mortal-
ity in patients with severe trauma. Anesth Analg 2011; 
113: 1003–1012.
24 Chapman MP, Moore EE, Ramos CR, Ghasabyan A, 
Harr JN, Chin TL, Stringham JR, Sauaia A, Silliman 
CC, Banerjee A: Fibrinolysis greater than 3% is the 
critical value for initiation of antifibrinolytic therapy. J 
Trauma Acute Care Surg 2013; 75: 961–967.
25 Schlimp CJ, Voelckel W, Inaba K, Maegele M, 
Schochl H: Impact of fibrinogen concentrate alone 
or with prothrombin complex concentrate (+/– fresh 
frozen plasma) on plasma fibrinogen level and fibrin-
based clot strength (FIBTEM) in major trauma: a ret-
rospective study. Scand J Trauma Resusc Emerg Med 
2013; 21: 74.
26 Schochl H, Schlimp CJ, Voelckel W: Perioperative 
 coagulation management in multiple trauma patients 
based on viscoelastic test results (in German). Un-
fallchirurg 2014; 117: 111–117.
27 Schochl H, Forster L, Woidke R, Solomon C, Voelckel 
W: Use of rotation thromboelastometry (ROTEM) to 
achieve successful treatment of polytrauma with fi-
brinogen concentrate and prothrombin complex con-
centrate. Anaesthesia 2010; 65: 199–203.
28 Schochl H, Cotton B, Inaba K, Nienaber U, Fischer H, 
Voelckel W, Solomon C: FIBTEM provides early pre-
diction of massive transfusion in trauma. Crit Care 
2011; 15:R265.
29 Nakayama Y, Nakajima Y, Tanaka KA, Sessler DI, 
Maeda S, Iida J, Ogawa S, Mizobe T: Thromboelastom-
etry-guided intraoperative haemostatic management 
reduces bleeding and red cell transfusion after paediat-
ric cardiac surgery. Br J Anaesth 2015; 114: 91–102.
30 Casutt M, Konrad C, Schuepfer G: Effect of rivaroxa-
ban on blood coagulation using the viscoelastic coagu-
lation test ROTEMTM. Anaesthesist 2012; 61: 948–953.
31 Franchini M: The platelet function analyzer (PFA-
100): an update on its clinical use. Clin Lab 2005; 51: 
367–372.
32 Görlinger K, Dirkmann D, Hanke AA, Kamler M, Kot-
tenberg E, Thielmann M, Jakob H, Peters J: First-line 
therapy with coagulation factor concentrates com-
bined with point-of-care coagulation testing is asso-
ciated with decreased allogeneic blood transfusion in 
cardiovascular surgery: a retrospective, single-center 
cohort study. Anesthesiology 2011; 115: 1179–1191.
33 Hazarbasanov D, Velchev V, Finkov B, Postadjian A, 
Kostov E, Rifai N, Aradi D: Tailoring clopidogrel dose 
according to multiple electrode aggregometry de-
creases the rate of ischemic complications after percu-
taneous coronary intervention. J Thromb Thromboly-
sis 2012; 34: 85–90.
34 Chowdhury M, Shore-Lesserson L, Mais AM, Leyvi G: 
Thromboelastograph with platelet mappingTM predicts 
postoperative chest tube drainage in patients under-
going coronary artery bypass grafting. J Cardiothorac 
Vasc Anesth 2014; 28: 217–223.
35 Carroll RC, Chavez JJ, Snider CC, Meyer DS, Muenchen 
RA: Correlation of perioperative platelet function and 
coagulation tests with bleeding after cardiopulmonary 
bypass surgery. J Lab Clin Med 2006; 147: 197–204.
36 Yu PJ, Cassiere HA, Dellis SL, Manetta F, Stein J, Hart-
man AR: P2y12 platelet function assay for assessment 
of bleeding risk in coronary artery bypass grafting. J 
Cardiac Surg 2014; 29: 312–316.
37 Dietrich GV, Schueck R, Menges T, Kiesenbauer NP, 
Fruehauf AC, Marquardt I: Comparison of four 
methods for the determination of platelet function 
in whole blood in cardiac surgery. Thromb Res 1998; 
89: 295–301.
38 Slaughter TF, Sreeram G, Sharma AD, El-Moalem H, 
East CJ, Greenberg CS: Reversible shear-mediated 
platelet dysfunction during cardiac surgery as assessed 
by the PFA-100 platelet function analyzer. Blood Co-
agul Fibrinolysis  2001; 12: 85–93.
39 Alstrom U, Granath F, Oldgren J, Stahle E, Tyden H, 
Siegbahn A: Platelet inhibition assessed with Veri-
fynow, flow cytometry and Platelet Mapping in pa-
tients undergoing heart surgery. Thromb Res 2009; 
124: 572–577.
40 Orlov D, McCluskey SA, Selby R, Yip P, Pendergrast J, 
Karkouti K: Platelet dysfunction as measured by a 
point-of-care monitor is an independent predictor of 
high blood loss in cardiac surgery. Anesth Analg 2014; 
118: 257–263.
41 Palmer JD, Sparrow OC, Iannotti F: Postoperative 
 hematoma: a 5-year survey and identification of avoid-
able risk factors. Neurosurgery 1994; 35: 1061–1065.
42 Naidech AM, Bernstein RA, Levasseur K, Bassin SL, 
Bendok BR, Batjer HH, Bleck TP, Alberts MJ: Platelet 
activity and outcome after intracerebral hemorrhage. 
Ann Neurol 2009; 65: 352–356.
43 Bachelani AM, Bautz JT, Sperry JL, Corcos A, Zenati 
M, Billiar TR, Peitzman AB, Marshall GT: Assessment 
of platelet transfusion for reversal of aspirin after trau-
matic brain injury. Surgery 2011; 150: 836–843.
44 Campbell PG, Sen A, Yadla S, Jabbour P, Jallo J: Emer-
gency reversal of antiplatelet agents in patients pre-
senting with an intracranial hemorrhage: a clinical 
 review. World Neurosurg 2010; 74: 279–285.
45 Nishijima DK, Zehtabchi S, Berrong J, Legome E: Util-
ity of platelet transfusion in adult patients with trau-
matic intracranial hemorrhage and preinjury antiplate-
let use: a systematic review. J Trauma Acute Care Surg 
2012; 72: 1658–1663.
46 Davis PK, Musunuru H, Walsh M, Cassady R, Yount 
R, Losiniecki A, Moore EE, Wohlauer MV, Howard J, 
Ploplis VA, Castellino FJ, Thomas SG: Platelet dys-
function is an early marker for traumatic brain in-
jury-induced coagulopathy. Neurocrit Care 2013; 18: 
201–208.
47 Bansal V, Fortlage D, Lee J, Doucet J, Potenza B, Co-
imbra R: A new clopidogrel (Plavix) point-of-care 
assay: rapid determination of antiplatelet activity in 
trauma patients. J Trauma 2011; 70: 65–70.
48 Solomon C, Traintinger S, Ziegler B, Hanke A, Rahe-
Meyer N, Voelckel W, Schochl H: Platelet function fol-
lowing trauma. A multiple electrode aggregometry 
study. Thromb Haemost 2011; 106: 322–330.
49 Mahambrey T, Pendry K, Nee A, Bonney S, Nee PA: 
Critical care in emergency department: massive haem-
orrhage in trauma. Emerg Med J 2013; 30: 9–14.
50 Spahn DR, Rossaint R: Coagulopathy and blood com-
ponent transfusion in trauma. Br J Anaesth 2005; 95: 
130–139.
51 Theusinger OM, Baulig W, Seifert B, Emmert MY, 
Spahn DR, Asmis LM: Relative concentrations of hae-
mostatic factors and cytokines in solvent/detergent-
treated and fresh-frozen plasma. Br J Anaesth 2011; 
106: 505–511.
52 Theusinger OM, Spahn DR, Ganter MT: Transfusion 
in trauma: why and how should we change our current 
practice? Curr Opin Anaesthesiol 2009; 22: 305–312.
53 Godje O, Gallmeier U, Schelian M, Grunewald M, 
Mair H: Coagulation factor XIII reduces postoperative 
bleeding after coronary surgery with extracorporeal 
circulation. Thorac Cardiovasc Surg 2006; 54: 26–33.
54 Theusinger OM: The inhibiting effect of factor XIII on 
hyperfibrinolysis. Anesth Analg 2012; 114: 1149–1150.
55 Schochl H, Nienaber U, Hofer G, Voelckel W, Jambor C, 
Scharbert G, Kozek-Langenecker S, Solomon C: Goal-
directed coagulation management of major trauma pa-
tients using thromboelastometry (ROTEM)-guided ad-
ministration of fibrinogen concentrate and prothrombin 
complex concentrate. Crit Care 2010; 14:R55.
56 Sorensen B, Spahn DR, Innerhofer P, Spannagl M, 
Rossaint R: Clinical review: prothrombin complex 
concentrates – evaluation of safety and thrombogenic-
ity. Crit Care 2011; 15: 201.
57 Preston FE, Laidlaw ST, Sampson B, Kitchen S: Rapid 
reversal of oral anticoagulation with warfarin by a pro-
thrombin complex concentrate (Beriplex): Efficacy and 
safety in 42 patients. Br J Haematol 2002; 116: 619–624.
58 Nienaber U, Innerhofer P, Westermann I, Schochl H, 
Attal R, Breitkopf R, Maegele M: The impact of 
fresh frozen plasma vs coagulation factor concen-
trates on morbidity and mortality in trauma-associ-
ated  haemorrhage and massive transfusion. Injury 
2011; 42: 697–701.
59 Pape HC, Neugebauer E, Ridley Saxon A, Chiara O, 
Nielsen TG., Christensen CM: Cost-drivers in acute 
treatment of severe trauma in Europe: a systematic 
 review of literature. Eur J Trauma Emerg Surg 2009; 35: 
61–66.
60 Theusinger OM, Stein P, Spahn DR: Transfusion strat-
egy in multiple trauma patients. Curr Opin Crit Care 
2014; 20: 646–655.
61 Theusinger OM, Stein P, Spahn DR: Applying ‘patient 
blood management’ in the trauma center. Curr Opin 
Anaesthesiol 2014; 27: 225–232.
62 Ruggeri ZM, Mannucci PM, Lombardi R, Federici AB, 
Zimmerman TS: Multimeric composition of factor 
VIII/von Willebrand factor following administration 
of DDAVP: implications for pathophysiology and 
therapy of von Willebrand’s disease subtypes. Blood 
1982; 59: 1272–1278.
63 Castaman G, Goodeve A, Eikenboom J, European 
Group on von Willebrand Disease: Principles of care 
for the diagnosis and treatment of von Willebrand dis-
ease. Haematologica 2013; 98: 667–674.
64 Beynon C, Sakowitz OW, Unterberg AW: Multiple 
electrode aggregometry in antiplatelet-related intra-
cerebral haemorrhage. J Clin Neurosci 2013; 20: 1805–
1806.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
5/
27
/2
01
6 
11
:5
5:
08
 A
M
65 Theusinger OM, Levy JH: Point of care devices for as-
sessing bleeding and coagulation in the trauma patient. 
Anesthesiol Clin 2013; 31: 55–65.
66 O’Keeffe T, Refaai M, Tchorz K, Forestner JE, Sarode 
R: A massive transfusion protocol to decrease blood 
component use and costs. Arch Surg 2008; 143: 686–
690; discussion 690–691.
67 Despotis GJ, Grishaber JE, Goodnough LT: The effect 
of an intraoperative treatment algorithm on physi-
cians’ transfusion practice in cardiac surgery. Trans-
fusion 1994; 34: 290–296.
68 Spiess BD, Gillies BS, Chandler W, Verrier E: Changes 
in transfusion therapy and reexploration rate after 
 institution of a blood management program in cardiac 
surgical patients. J Cardiothorac Vasc Anesth 1995; 9: 
168–173.
69 Shore-Lesserson L, Manspeizer HE, DePerio M, 
 Francis S, Vela-Cantos F, Ergin MA: Thromboelastog-
raphy-guided transfusion algorithm reduces transfu-
sions in complex cardiac surgery. Anesth Analg 1999; 
88: 312–319.
70 Nuttall GA, Oliver WC, Santrach PJ, Bryant S, Dearani 
JA, Schaff HV, Ereth MH: Efficacy of a simple intra-
operative transfusion algorithm for nonerythrocyte 
component utilization after cardiopulmonary bypass. 
Anesthesiology 2001; 94: 773–781; discussion 5A–6A.
71 Capraro L, Kuitunen A, Salmenpera M, Kekomaki R: 
On-site coagulation monitoring does not affect hemo-
static outcome after cardiac surgery. Acta Anaesthesiol 
Scand 2001; 45: 200–206.
72 Royston D, von Kier S: Reduced haemostatic factor 
transfusion using heparinase-modified thrombelastog-
raphy during cardiopulmonary bypass. Br J Anaesth 
2001; 86: 575–578.
73 Avidan MS, Alcock EL, Da Fonseca J, Ponte J, Desai 
JB, Despotis GJ, Hunt BJ: Comparison of structured 
use of routine laboratory tests or near-patient assess-
ment with clinical judgement in the management of 
bleeding after cardiac surgery. Br J Anaesth 2004; 92: 
178–186.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
5/
27
/2
01
6 
11
:5
5:
08
 A
M
